EBOS Group Limited (EBOS) notes the announcement by the Australian Competition and Consumer Commission (ACCC) today that it will not oppose the proposed acquisition of LifeHealthcare announced on 9 December 2021.
The transaction remains subject to satisfaction of certain conditions precedent and the parties continue to work diligently towards completion of the transaction, which is expected in FY22.
The ACCC will not oppose the proposed acquisition of Australian Pacific Health Supplies TopCo1 Pty Limited and its subsidiaries (Pacific Health Group) by EBOS Group Limited (ASX: EBO), through its subsidiary EBOS Medical Devices Australia Pty Limited.
EBOS and Pacific Health Group distribute a range of medical devices to private and public hospitals and to clinicians. Pacific Healt h Group also manufactures and distributes allografts through its Australian Biotechnologies business. In general, the majority of the parties’ offerings are complementary and not in direct competition.
A copy of the statement by the ACCC is attached.
Comments from our readers
No comments yet
Add your comment:
Related News:
TRU - Resignation of CEO, Martin Dillon
HGH - Heartland confirms endorsement of TSB Heartland Bank CEO
Devon Funds Morning Note - 02 October 2026
TEM - Transaction in Own Shares
SPK - Notice of Annual Meeting and Proxy Form
October 2nd Morning Report
AFI - Dividend Guidance for FY27 and Move to Quarterly Dividends
SKO - Serko FY27 Interim Results Announcement Date - 16 November
NZK - Proposed Share Transaction Requiring Shareholder Approval
BIF - capital commitment made to BIF
See IRG research reports
